U.S., June 18 -- ClinicalTrials.gov registry received information related to the study (NCT07023965) titled 'Follow-up Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-L)' on June 06.
Brief Summary: The goal of this observational study is to learn about the long-term effects of Donaperminogene Seltoplasmid Injection (NL003) in participants who have been received drug NL003 or placebo at least one dose from the parent phase III clinical study to treat their critical limb ischemia (CLI). The main questions it aims to answer are:
* First, what medical problems do participants have after taking drug NL003 to treat CLI?
* Second, does drug NL003 make CLI participants live longer without serious problems (amputations or targe...